SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Healthcare >

Oxis International Inc. (OXIS)

OXIS RSS Feed
Add OXIS Price Alert      Hide Sticky   Hide Intro
Moderator: CashBowski, BDavid5
Search This Board: 
Last Post: 8/16/2017 8:04:35 PM - Followers: 176 - Board type: Free - Posts Today: 37


 

Oxis International Inc.

Below shows OXS-1550 WORKING - Soon to enter Phase II with FDA!

Overview

Treating Non-Hodgkin's lymphoma

OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550 and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.

Treating triple-negative breast cancer

Our lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.

Treating multiple myeloma

Our lead drug candidate, OXS-4235, also a small molecule therapeutic candidate, targets the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone.


Management



 

Company Website
http://oxis.com

 


Corporate Overview - Presentation
Fall 2015
Click the link: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10968247


 




 





 

 

OXIS Conference Call  March 31, 2015

CEO Interview with The Wolf of Weedstreet

 

SCIENTIFIC ADVISORY BOARD

XIANG-QUN (SEAN) XIE, M.D., Ph.D., EMBA

Sean Xie, MD, PhD, EMBA is a tenured Professor at the Department of Pharmaceutical Sciences/Drug Discovery Institute at University of Pittsburgh and Associate Dean for Research Innovation at the School of Pharmacy. He is Principal Investigator of an integrated research laboratory of CompuGroup, BioGroup and ChemGroup, and Founding Director of Computational Chemical Genomics Screening Center. Dr. Xie is also Director/PI of NIH funded National Center of Excellence for Computational Drug Abuse Research. Dr. Xie holds joint faculty positions at the Departments of Computational System Biology and Structural Biology, and Pittsburgh Cancer Institute MT/DD Program. He serves as an invited guest editor for AAPS Journal, Editorial Board of American Journal of Molecular Biology, and Associate Editor of BMC Pharmacology and Toxicology. In 2013, he was named an honorary professor of Chinese Academy of Medical Sciences & Peking Union Medical College. Dr. Xie is a recipient of the 2014 American Association of Pharmaceutical Scientists (AAPS) Outstanding Research Achievement Award.

JAMES J. MULE, Ph.D.

Dr. James J. Mule, Ph.D. serves as an Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center. He then moved to Palo Alto, Calif., where he was involved in the birth of two startup companies while an adjunct faculty member in the Department of Surgery, Stanford University. He moved to Ann Arbor, Mich., as the Director of the Tumor Immunology and Immunotherapy Clinical Research Programat the University of Michigan Comprehensive Cancer Center. Dr. Mule is recognized for his translational research studies in cancer immunotherapy. His research group is involved in vaccine strategies and other approaches to stimulate the immune system to recognize and destroy tumors. The work in these areas has helped to develop new treatments for advanced cancer patients. Dr. Mule serves on the Advisory Boards of seven NCI-designated Cancer Centers and was a member of the NCI’s Board of Scientific and Clinical Counselors. He serves as Chair of the Cellular, Tissue and Gene Therapy Advisory Committee of CBER, FDA, is a Special Government Employee of the NCI and the FDA. Dr. Mule is recognized for his research and clinical contributions to cancer immunotherapy, particularly in solid tumors.

STEPHEN M. CHANG, Ph.D.

Dr. Stephen M. Chang is Vice President-Research & Development at New York Stem Cell Foundation, Chief Scientific Officer at Stemgent, Inc., and Independent Director at MultiCell Technologies, Inc. He is on the Board of Directors at MultiCell Technologies, Inc. Dr. Chang was previously employed as Chief Scientific Officer & Vice President by Canji, Inc., Chief Scientific Officer & Vice President by Schering-Plough Research Institute, and President & Chief Executive Officer by MultiCell Immunotherapeutics, Inc. He also served on the board at Histogen, Inc. He received his undergraduate degree from the University of Michigan and a doctorate degree from the University of California, Irvine.

LISA A. HAILE, Ph.D.

Dr. Haile has special technical experience in molecular biology, immunology, plant biotechnology, including transgenic plants, cell biology, diagnostics, therapeutics, theranostics, virology, drug delivery systems, host-vector systems, high throughput screening and bioinformatics. She has particular experience with patentability, non-infringement and validity opinions; licensing strategies; FDA counseling; due diligence work in connection with venture capital, private and public financing; mergers and acquisitions in the life sciences industry; and strategic counseling for comprehensive life sciences patent portfolio management. Dr. Lisa Haile concentrates on patent protection.

 

Information on Multiple Myeloma & Cannabidiol (CBD)

After studying the effects of cannabidiol on multiple myeloma cells, researchers found that; “CBD by itself or in synergy with BORT strongly inhibited growth, arrested cell cycle progression and induced MM cells death by regulating the ERK, AKT and NF-κB pathways with major effects in TRPV2+ cells.”

They conclude that; “These data provide a rationale for using CBD to increase the activity of proteasome inhibitors in MM.”

The study, which validates a recent National Institute of Health study which also found that cannabidiol can inhibit cancer cells, was conducted by researchers at the School of Pharmacy at the University of Camerino in Italy.

 Chart

Stock Information:


 
OXIS
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
OXIS News: Quarterly Report (10-q) 08/11/2017 04:50:22 PM
OXIS News: Current Report Filing (8-k) 07/25/2017 09:37:37 AM
OXIS News: Withdrawal of Registration Statement (rw) 07/24/2017 11:34:32 AM
OXIS News: Current Report Filing (8-k) 06/26/2017 08:01:21 AM
OXIS News: Information Statement - All Other (definitive) (def 14c) 05/12/2017 04:03:59 PM
PostSubject
#9588  Sticky Note The topic of this board is OXIS. The CashBowski 03/31/17 11:03:34 AM
#10920   I listened to every single word of the bmg2020 08/16/17 08:04:35 PM
#10919   Thanks, friggin work AlleggsoneBasketcase 08/16/17 07:38:01 PM
#10918   I emailed them for a recording/play link. BobDoleYahoo 08/16/17 07:32:13 PM
#10916   Great run today to .12+. Waiting to hit .20 DRCJRE 08/16/17 06:21:10 PM
#10915   cant find the cc recording. any help? AlleggsoneBasketcase 08/16/17 05:49:21 PM
#10914   PROVEN TRACK RECORD MANAGEMENT! MrBond007 08/16/17 05:16:58 PM
#10913   X amount in old becomes y amount in steamed_turtle 08/16/17 05:12:21 PM
#10912   CC described drug pipelines and rationale for reverse Subsea1 08/16/17 05:07:07 PM
#10911   I WAS RIGHT ABOUT EVERYTHING!!!! I said BobDoleYahoo 08/16/17 05:04:10 PM
#10910   So, I'm new enough to all this that txbuddha 08/16/17 05:02:16 PM
#10909   A shame they never mentioned when the RS MrBond007 08/16/17 05:01:51 PM
#10908   New CMO to be named soon. 3 drugs txbuddha 08/16/17 05:01:08 PM
#10907   I expect tomorrow it to shoot to $1 MrBond007 08/16/17 05:01:06 PM
#10906   That couldn't be any better CC for OXIS!! bmg2020 08/16/17 05:00:26 PM
#10904   After the closing bell at 4:15pm EST. The txbuddha 08/16/17 04:24:34 PM
#10903   Will CC be streamed online or do you not4you_25 08/16/17 04:00:29 PM
#10902   Last CC was to Update us on Phase Gibba 08/16/17 03:33:05 PM
#10901   CC is not till after the bell.. bmg2020 08/16/17 02:14:43 PM
#10900   Profit taking or shorts pushing it down to steamed_turtle 08/16/17 02:10:34 PM
#10899   Conference call must have really sucked all I Bishop123 08/16/17 02:10:15 PM
#10898   $OXIS flash dip to 08 Cheds 08/16/17 02:04:33 PM
#10897   What is happening Soup Stock 08/16/17 01:59:44 PM
#10896   Volume $OXIS Cheds 08/16/17 01:47:58 PM
#10895   Oxis to $20 MrBond007 08/16/17 01:45:00 PM
#10894   Oxis to the moon baby! :) MrBond007 08/16/17 01:44:38 PM
#10893   The FACTS are that the CC is to bmg2020 08/16/17 01:03:28 PM
#10892   Same old OXIS, Different Huckleberries. Gibba 08/16/17 12:21:47 PM
#10891   LOOK - FACTS After Last Conference Call? Gibba 08/16/17 12:06:18 PM
#10889   Moving avg,.about to swing way up Corribus 08/16/17 10:02:54 AM
#10888   Unbelievable moving higher on thin air! micar 08/16/17 09:51:58 AM
#10887   Oxis to the moon! :) MrBond007 08/16/17 09:31:30 AM
#10886   Any opinions on oxis today? Corribus 08/16/17 09:10:51 AM
#10885   4:15 http://www.baystreet.ca/viewarticle.aspx?id=471309 BAMBOOZLER 08/16/17 06:51:30 AM
#10884   I would love to find and call out deadjim 08/16/17 12:31:10 AM
#10883   What time is the CC and what is Pennybuster11 08/15/17 11:05:31 PM
#10882   Tomorrow's CC will shed light on all doubts! BAMBOOZLER 08/15/17 08:01:56 PM
#10881   So is this a pump or not? I TRADEdeez 08/15/17 07:47:40 PM
#10880   Clay is involved I'm out this is going licnevarez 08/15/17 07:26:55 PM
#10879   See Everyone 30 Days After Reverse Split. Gibba 08/15/17 06:57:15 PM
#10878   The next big wall L2 cant mm has mcord 08/15/17 06:39:16 PM
#10876   * * $OXIS Video Chart 08-15-17 * * ClayTrader 08/15/17 05:40:54 PM
#10875   It looks like its going to .20 Pennybuster11 08/15/17 04:04:36 PM
#10874   HAHA seriously. This stock is on billymack 08/15/17 03:47:10 PM
#10872   Why flush? capttom1 08/15/17 02:43:30 PM
#10871   looks great. flushed today already VivaLasVegas 08/15/17 01:37:52 PM
#10870   oxis to the moon baby! :) Yeah baby MrBond007 08/15/17 01:36:42 PM
#10869   who cares zeekhoe 08/15/17 01:28:29 PM
#10868   Oxis to $.20 soon MrBond007 08/15/17 01:27:16 PM
#10867   Congrats OXIS'ers. Hope this helps out MCET someday. VivaLasVegas 08/15/17 01:25:58 PM
#10865   You are paranoid not sure who you are MrBond007 08/15/17 11:56:17 AM
PostSubject